Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomizedcontrolled trial

References

• Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry 2003; 37: 55–56
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr, Tollefson G D, Tran P V. Efficacy of olanzapine: an overview of pivotal clinical trials. Journal of Clinical Psychiatry 1997; 58: 7–12
   PubMed Web of Science ®Google Scholar
• Tollefson G D, Beasley C M, Tran P, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997; 154: 457–465
   PubMed Web of Science ®Google Scholar
• Allison D B, Mentore J L, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686–1696
   PubMed Web of Science ®Google Scholar
• Gupta S, Droney T, Al-Samarrai S, Keller P, Frank Bl. Olanzapine: weight gain and therapeutic efficacy. Journal of Clinical Psychopharmacology 1999; 19: 273–274
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr, Tollefson G D, Tran P V. Efficacy of olanzapine: an overview of pivotal clinical trials. Journal of Clinical Psychiatry 1997; 58: 13–17
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Gu H, Green AI, et al. Clinical correlates of weight gain in first episode patients treated with olanzapine. Schizophrenia Research 2003; 60: 372
   Web of Science ®Google Scholar
• Kinon B J, Basson B R, Gilmore J A, Tollefson G D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry 2001; 62: 92–100
   PubMed Web of Science ®Google Scholar
• Jones B, Basson B R, Walker D J, Crawford A M, Kinon B J. Weight change and atypical antipsychotic treatment in patients with schizophrenia. Journal of Clinical Psychiatry 2001; 6: 41–44
   Google Scholar
• Ruschena D, Mullen P E, Burgess P, et al. Sudden death in psychiatric patients. British Journal of Psychiatry 1998; 172: 331–336
   PubMed Web of Science ®Google Scholar
• Lambert J R, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Medical Journal of Australia 2003; 178: S67–S70
   PubMedGoogle Scholar
• Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie 2001; 46: 549–555
   PubMed Web of Science ®Google Scholar
• Glick I D, Fryburg D, O'sullivan R L, Siu C, Simpson G. Ziprasidone's benefits versus Olanzapine on weight and insulin resistance. New Orleans, LA 8 May, 2001, American Psychiatric Association Annual Meeting New Research Poster Session 261
   Google Scholar
• Conley R R, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2001; 158: 765–774
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry 2003; 64: 598–604
   PubMed Web of Science ®Google Scholar
• Alison D B, Casey D E. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 2001; 62: 22–31
   Google Scholar
• Seidell J C. Society and personal costs of obesity. Experimental and Clinical Endocrinology and Diabetes 1998; 106: 7–9
   PubMed Web of Science ®Google Scholar
• Baptista T. Body weight gain induced by antipsychotic drugs. Acta Psychiatric Scandinavica 1999; 100: 3–16
   PubMed Web of Science ®Google Scholar
• McIntyre R, Mancini M, Basile V. Mechanisms of antipsychotic-induced weight gain. Journal of Clinical Psychiatry 2001; 62: 23–29
   PubMedGoogle Scholar
• Cavazzoni P, Tanaka Y, Roychowdhury S M, Breier A, Allison D B. Nizatindine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. European Neuropsychopharmacology 2003; 13: 81–85
   PubMed Web of Science ®Google Scholar
• Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. European Neuropsychopharmacology 2001; 11: 181–182
   PubMed Web of Science ®Google Scholar
• Baruch R, Poulin M, Thakur A. Amantadine induces weight loss in patients treated with olanzapine. Schizophrenia Research 2002; 53: 159
   Google Scholar
• Wilcox J A, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990; 23: 144–146
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry 2002; 159: 1058–1060
   PubMed Web of Science ®Google Scholar
• Tafunski T, Chojnacka H. Sibutramine-associated psychotic episode. American Journal of Psychiatry 2000; 157: 2056–2057
   Google Scholar
• Dinan T G, Tobin A. Orlistat in the management of antipsychotic-induced weight gain: two case reports. Journal of Serotonin Research 2001; 7: 14–15
   Google Scholar
• Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. Journal of Clinical Psychopharmacology 2000; 20: 716–717
   Google Scholar
• Hilger E, Quiner S, Ginzel I. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. Journal of Clinical Psychopharmacology 2002; 22: 68–70
   PubMed Web of Science ®Google Scholar
• Birt J. Management of weight gain associated with antipsychotics. Annals of Clinical Psychiatry 2003; 15: 49–58
   PubMedGoogle Scholar
• Werneke U, Taylor D, Sanders T A. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International Clinical Psychopharmacology 2002; 17: 145–160
   Web of Science ®Google Scholar
• Menza M, Vreeland B, Minsky S, Gara M, Radler D, Sakowitz R D. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. Journal of Clinical Psychiatry 2004; 65: 471–477
   PubMed Web of Science ®Google Scholar
• Centorrino F, Wurtzmann J J, Duca KK, et al. Comprehensive weight loss programs for overweight subjects treated with atypical antipsychotics. Philadelphia, PA 18 – 23 May, 2002, Poster presented at 155th American Psychiatric Association Annual Meeting
   Google Scholar
• Ball M P, Coons V B, Buchanan R W. A program for treating Olanzapine-related weight gain. Psychiatric Services 2001; 52: 967–969
   PubMed Web of Science ®Google Scholar
• Littrell K H, Hilligoss N M, Kirshner C D, Petty R G, Johnson C G. The effects of an educational intervention on antipsychotic-induced weight gain. Journal of Nursing Scholarship 2003; 35: 237–241
   PubMed Web of Science ®Google Scholar
• Nguyen C T, Ortiz T, Franklin D, Yu B, Maguire G A. Nutritional education in minimising weight gain associated with antipsychotic therapy. New Orleans 7 May, 2001, NR158. Presented at the 154th American Psychiatric Association Annual Meeting
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology, Rev ed. U.S. National Institute of Health, Psychopharmacology Research Branch, Rockville, MD 1976
   Google Scholar
• Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry 2001; 46: 549–555
   PubMed Web of Science ®Google Scholar
• Barham P. Manfred Bleuler and the understanding of psychosis. Psychosis: understanding and treatment, J Ellwood. University of London, Goldsmiths' College, London, UK 1995; 1: 23–33
   Google Scholar